Drawing for CONVERSION

USPTO serial 98930834

CONVERSION

Reviewed by CopyMark Law Group

Status 748
Filing date
Status date
Registration date
—
Examiner
BARREDA, AMBER KYLEE
Law office
TMEG LAW OFFICE 103

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with CONVERSION?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Deborah L. Lively

Deborah L. Lively Pierson Ferdinand LLP8604 Turtle Creek Blvd #12274Dallas, TX 75225United States

Goods and services

ClassDescriptionStatusFirst use
001Reagents for scientific and research useACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 17, 2026SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Sep 16, 2026IUAFUSE AMENDMENT FILED—
Sep 16, 2026EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Sep 2, 2026CORVREVIEW OF CORRESPONDENCE COMPLETE—
Sep 2, 2026AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Aug 25, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 24, 2026EX1GSOU EXTENSION 1 GRANTED—
May 5, 2026NREVNOTICE OF REVIVAL - E-MAILED—
May 5, 2026TPEXSOU EXTENSION RECEIVED WITH TEAS PETITION—
May 5, 2026PETGPETITION TO REVIVE-GRANTED—
May 5, 2026PROATEAS PETITION TO REVIVE RECEIVED—
May 1, 2026TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 1, 2026ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 1, 2026REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Apr 27, 2026MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Apr 27, 2026ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Mar 23, 2026EXT1SOU EXTENSION 1 FILED—
Sep 23, 2025NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jul 29, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 29, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 23, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jun 23, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 12, 2025DOCKASSIGNED TO EXAMINER—
Dec 31, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 31, 2024NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance